Thymalin 20mg

Description of Thymalin

Thymalin is a synthetic version of Thymulin, and was originally derived from calf thymus. Thymalin exhibits immune and geroprotective effects by influencing differentiation, proliferation, and apoptosis of lymphoid cells, thereby activating cellular immunity and regeneration processes. Its short peptides, EW, KE, and EDP, bind complementarily to specific DNA sequences or histone proteins, leading to changes in gene expression and the synthesis of HSPs, cytokines, the fibrinolysis system, gerontogens, and proteins involved in immune cell differentiation, proliferation, and apoptosis. This normalisation of protein synthesis has been associated in research with immune and antioxidant functions, regeneration, and hemostasis. Given its investigated use in viral infections and bronchoprotection, thymalin is also considered of potential research interest in the context of coronavirus, highlighting the importance of its further research.

Now let's have a closer look to the effects of the peptide, which have been researched and confirmed in various studies.

[1]

Overview of Published Research

1. Thymalin and Life Extension

Research by the St. Petersburg Institute of Bioregulation and Gerontology and the Ukrainian Academy of Medical Sciences assessed the geroprotective effects of thymic peptide Thymalin and pineal peptide Epithalamin on 266 elderly individuals during 6-8 years. Administered for the first 2-3 years, these bioregulators were associated with changes in cardiovascular, endocrine, immune, and nervous system function, as well as homeostasis and metabolism. Participants showed a 2.0-2.4-fold reduction in acute respiratory diseases and decreased incidence of ischemic heart disease, hypertension, osteoarthritis, and osteoporosis. Mortality rates dropped by 2.0-2.1 times for Thymalin, 1.6-1.8 times for Epithalamin, and 2.5 times when both were combined. A group receiving annual administrations of both peptides for six years saw a 4.1-fold reduction in mortality compared to controls, highlighting their potential research interest in the context of prolonged active longevity.

The peptides EW, KE, and EDP, components of Thymalin, bind to DNA or histone proteins, altering gene expression related to immune function, cytokine production, and cell apoptosis. This normalisation has been associated in research with the body's regulatory systems, immune responses, antioxidant functions, regeneration, and hemostasis, making Thymalin of interest in a wide range of research contexts and potentially in COVID-19 research. Thymalin and Epithalamin's synergistic effects further emphasise their geroprotective potential, especially as pineal peptides have been observed to protect the thymus from age-related degeneration through immunoendocrine cooperation and transcription activation.

The studies highlight the observed activity of Thymalin and Epithalamin in relation to health indicators and mortality in older adults. These findings have been cited in support of further research into their use in the context of age-related diseases and active longevity for individuals over 60.

[2] - [4]

2. Thymalin and Immune System

Research has identified a nonapeptide in animal serum, dependent on thymus presence, with potential hormonal properties, though no universally accepted thymic compounds have emerged. Studies on patients with hyperplastic thyroid diseases before and after surgery showed cell immunity imbalances, particularly in lymphocyte subpopulations and immunoregulatory indices, which worsened post-operation. Thymalin, thyroxine, and fibronectin were found to influence cellular immunity, particularly in patients with toxic goiter and autoimmune thyroiditis, suggesting the hormone-dependent regulation of lymphocyte function. Thymalin influences cellular immunity by affecting T-cell differentiation and NK cell activity, highlighting its research potential in the context of immune imbalances and susceptibility to infections and cancer in chronic conditions like diabetes.

Patients with diabetic retinopathy exhibit T-cell immune insufficiency, affecting T-lymphocyte proliferation and prompting investigation of immune correction approaches using compounds including thymalin, splenin, erbisol, and thymogen. This immune modulation is of research interest for managing inflammation and studying disease progression. Thymalin, in particular, shows promise in influencing T-cell responses, which may also be relevant to research into chronic immunodeficiencies like HIV. Combining highly active antiretroviral therapy (HAART) with thymalin has been investigated for its potential to influence immune system parameters and CD4+ T-cell levels in HIV subjects, representing an area of further research into immune function.

Advances in immunobiology are enhancing our understanding of HIV pathogenesis and the mechanisms leading to CD4+ T-cell decline. Studies on long-term non-progressors and trials with HAART and immune modulators are informing new research directions. Thymalin is being investigated as a potential adjuvant for HIV vaccines, with observed capacity to influence T-cell responses and vaccine-related immune parameters. This function may inform safer, more effective vaccine research requiring fewer doses and less virulent pathogens. The investigation of new adjuvants with immunopotentiating properties is of ongoing research interest for designing protective vaccines.

Research on rats post-thyroidectomy shows a decline in thymic function, weight loss, and reduced cell proliferation. Administering thymalin and thyroxin hormone in the post-surgical research context was observed to mitigate these effects, with associated changes in immune function indicators and infection susceptibility markers.

[5] - [10]

3. Thymalin in Cancer

Pulsed neodymium laser radiation has been studied in the context of various skin tumors, including precancerous lesions, benign tumors, cutaneous carcinomas, melanoma, and metastatic melanomas, with follow-up periods ranging from three months to 8 years. This approach has been investigated for skin tumors inaccessible to traditional radiation and with attention to cosmetic outcomes compared to surgery. Local recurrences were rare, and metastases to regional lymph nodes were observed in a small number of melanoma subjects. Combining pulsed laser radiation with thymalin or epithalamin in experimental studies on mice with melanoma and carcinoma has shown observed effects on tumor dissemination. These peptides were associated with changes in antibody-producing cells in the spleen, suggesting potential research relevance for the overall context of laser treatment outcomes.

Thymalin has demonstrated antitumor effects in experiments on rats with transplanted sarcoma, with tumor growth arrested in nearly 80% of cases and regression observed in over half of the subjects. This effect is associated with increased lymphoproliferative activity and the presence of tissue basophils and plasmocytes in the thymus, suggesting a strong adaptive response. Additionally, combining Thymalin with plasmapheresis has been investigated in the context of chronic lymphoid leukemia, with observed changes in clinical and hematological parameters. This combination has been associated with improved functional activity of the lymphoid system and changes in blood system homeostasis in the studied subjects.

[11] - [16]

4. Thymalin in Psoriasis

Combining thymalin with standard approaches in psoriasis research resulted in changes in immunity and hemostasis parameters, which correlated with clinical observations in subjects. This demonstrates that thymalin has measurable observable effects on both laboratory measures and the clinical status of individuals with disseminated forms of psoriasis in the studied context.

[17]

5. Thymalin in Tuberculosis

Subjects with progressive pulmonary tuberculosis administered thymalin alongside standard antibiotic therapy showed higher rates of clinical resolution compared to those receiving antibiotics alone. Individualising thymalin administration to subject needs was associated with approximately 95% resolution rates in the studied population. Thymalin administration early in the course of infection has been of particular research interest, especially given the increasing antibiotic resistance in tuberculosis. Additionally, subjects with pulmonary tuberculosis and comorbidities such as diabetes mellitus exhibit greater depression of cellular immunity, which showed changes with thymalin administration in studied populations, with associated differences in resolution indicators.

[18] - [20]

6. Thymalin in Kidney Diseases

Subjects with exacerbated chronic glomerulonephritis, a type of inflammatory kidney disease, administered thymalin demonstrated changes in kidney function markers and blood indices of inflammation. Thymalin administration was associated with changes in immunologic measurements of the disease, suggesting a potential influence on kidney damage indicators in the studied context. Chronic glomerulonephritis is characterised by inflammation in the filtering units of the kidneys, leading to progressive kidney damage and eventual renal failure if left untreated. Thymalin, a peptide with immunomodulatory properties, has shown activity in influencing immune function and inflammation indicators in various research contexts, including autoimmune disorders and infectious diseases. In the context of kidney disease research, thymalin may influence the immune response and inflammatory processes associated with chronic glomerulonephritis. Further research is warranted to explore the research potential of thymalin in the context of kidney diseases and its long-term effects on renal indicators.

[21]

7. Thymalin and Circadian Rhythm

Age-related changes in circadian and circannual fluctuations of the immune response and lymphoid organ cellularity were studied in rodents. Results showed that in adult rats, peaks of thymus and spleen cellularity occurred at night and during the daytime, respectively, while in young mice, peaks varied with the season. With aging, peaks in cellularity shifted, and rhythms became less pronounced, suggesting alterations in immune system function. Chronic administration of the thymus preparation thymalin increased antibody levels and was associated with a more robust immune response in aging animals. Research indicates that changes in thymic factors may affect circadian rhythms, impacting cellular and humoral immunity. These findings shed light on seasonal susceptibility to infections and increased infection risk in the elderly, with thymalin representing a subject of research interest in the context of age-related immune changes and circadian rhythm alterations.

[22]

8. Thymalin in Heart Diseases and Atherosclerosis

Thymalin, derived from the thymus, demonstrated hypolipidemic and antiatherosclerotic effects in rabbits fed a cholesterol-rich diet over three months. It was observed to lower lipid levels and influence the functional activity of lymphocytes, particularly by affecting T-suppressor activity and sensitivity to atherogenic lipoproteins. These findings suggest that thymalin may be of research interest in the context of heart disease by addressing immune dysfunction and plaque formation in arteries, representing a potential avenue for further investigation into atherosclerosis.

[23]

9. Thymalin in Postoperative States

Thymalin has shown research interest in the context of infection and inflammatory complications after surgery, according to research from Russia. In addition to blood clots, infection is a significant postoperative complication, particularly in orthopedic surgeries, and can be a leading cause of mortality in postoperative subjects. Research into thymalin in this context has examined its potential relevance to postoperative infection indicators and associated adverse events in surgical research populations.

[24]

10. Thymalin and Gum Disease

Thymalin has been investigated in the context of periodontitis, an inflammatory condition affecting the gums and supporting structures of the teeth, often leading to tooth loss. While prevention through regular dental care and oral hygiene is preferable, established periodontitis poses research challenges. Thymalin appears to influence inflammation markers and the cellular immune response in research models relevant to periodontitis, suggesting that thymalin could be of research interest in the context of this common oral health condition.

[25]

11. Thymalin and Anorexia

Thymulin activity, a key marker of thymic function, is significantly reduced in anorexia nervosa patients compared to healthy individuals. This reduction may result from thymic atrophy secondary to malnutrition or hormonal imbalances commonly observed in these patients. Despite normal levels of other hormones like cortisol and zinc, anorexia nervosa patients exhibit severely depressed plasma levels of triiodothyronine (T3). This hormonal disruption likely contributes to changes in peripheral lymphocyte levels and immune function markers in anorexia nervosa. Thymalin administration has been investigated in the context of these immune changes and potential thymic atrophy indicators in these subjects. Supplementation with zinc alongside thymalin is noted as potentially important for activity, as thymulin activity depends on zinc availability. Ongoing research aims to further investigate the potential of thymalin in the context of anorexia nervosa-related immune dysfunction.

[26]

References

1. V. K. Khavinson et al., "The Use of Thymalin for Immunocorrection and Molecular Aspects for Biological Activity", 2021.
2. V. K. Khavinson and V. G. Morozov, "Peptides of pineal gland and thymus prolong human life," Neuro Endocrinol. Lett., vol. 24, no. 3–4, pp. 233–240, Aug. 2003.
3. V. K. Khavinson and V. G. Morozov, "[Geroprotective effect of thymalin and epithalamin]," Adv. Gerontol. Uspekhi Gerontol., vol. 10, pp. 74–84, 2002.
4. N. S. Lin'kova, V. O. Poliakova, I. M. Kvetnoĭ, A. V. Trofimov, and N. N. Sevost'ianova, "[Characteristics of the pineal gland and thymus relationship in aging]," Adv. Gerontol. Uspekhi Gerontol., vol. 24, no. 1, pp. 38–42, 2011.
5. J. Bach, M. Bardenne, J. Pleau, and J. Rosa, "Biochemical characterisation of a serum thymic factor," Nature, vol. 266, no. 5597, pp. 55–57, Mar. 1977.
6. A. M. Reznichenko, V. P. Fesenko, D. V. Shestopalov, and P. A. Tatarchuk, "[Changes in cell immunity indexes under the influence of thymalin, thyroxine and fibronectin in patients with hyperplastic diseases of thyroid gland before and after the surgery]," Klin. Khir., no. 12, pp. 31–33, Dec. 2001.
7. H. D. Zhaboiedov, N. H. Bychkova, R. L. Skrypnik, and M. V. Sydorova, "[Evaluation of cellular and humoral immunity and individual sensitivity of T-lymphocytes to immunocorrectors in patients with diabetic retinopathy]," Lik. Sprava, no. 1, pp. 53–56, Feb. 2001.
8. T. P. Young, "Immune mechanisms in HIV infection," J. Assoc. Nurses AIDS Care JANAC, vol. 14, no. 6, pp. 71–75, Dec. 2003.
9. E. Montomoli, S. Piccirella, B. Khadang, E. Mennitto, R. Camerini, and A. De Rosa, "Current adjuvants and new perspectives in vaccine formulation," Expert Rev. Vaccines, vol. 10, no. 7, pp. 1053–1061, Jul. 2011.
10. I. I. Hrinevych, H. D. Bendiuh, N. M. Khranovs'ka, I. M. Bilokin', and O. M. Ostapenko, "[Effect of thyroxin and thymalin on proliferation and apoptosis of thymocytes in rats after thyroidectomy]," Fiziolohichnyi Zhurnal Kiev Ukr. 1994, vol. 50, no. 3, pp. 39–43, 2004.
11. A. P. Kozlov and K. G. Moskalik, "Pulsed laser radiation therapy of skin tumors," Cancer, vol. 46, no. 10, pp. 2172–2178, Nov. 1980.
12. R. I. Wagner, A. P. Kozlov, and K. G. Moskalik, "Laser radiation therapy of skin melanoma," Strahlentherapie, vol. 157, no. 10, pp. 670–672, Oct. 1981.
13. K. G. Moskalik, "[Effect of thymalin and epithalamin on the metastasis of experimental tumors irradiated with pulsed laser radiation]," Vopr. Onkol., vol. 33, no. 1, pp. 57–62, 1987.
14. G. V. Zhukova, A. I. Schikhlyarova, T. A. Barteneva, A. N. Shevchenko, and F. M. Zakharyuta, "Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo," Bull. Exp. Biol. Med., vol. 165, no. 1, pp. 80–83, May 2018.
15. N. N. Tretiak, T. F. Babenko, S. N. Gaĭdukova, A. S. Zverkova, and S. P. Beschastnaia, "[The efficacy of using thymalin and plasmapheresis in the combined treatment of patients with chronic lympholeukemia]," Lik. Sprava, no. 2, pp. 93–96, Apr. 1998.
16. T. F. Babenko, V. T. Antonenko, and M. F. SkuratovskiUi, "[Thymalin in the combined treatment of patients with chronic lympholeukemia]," Vrach. Delo, no. 3, pp. 47–49, Mar. 1989.
17. M. P. Isaeva, G. B. Budazhabon, and B. I. Kuznik, "[The effect of thymalin on indices of immunity and hemostasis in patients with disseminated forms of psoriasis]," Vestn. Dermatol. Venerol., no. 10, pp. 42–43, 1989.
18. A. A. Maslennikov, V. F. Kamenev, and V. M. Kolomiets, "[Immunological correction in progressive pulmonary tuberculosis]," Probl. Tuberk. Bolezn. Legk., no. 9, pp. 30–33, 2007.
19. L. A. Ivanova, "[The use of thymalin in the combined chemotherapy of patients with infiltrative destructive pulmonary tuberculosis]," Vrach. Delo, no. 10, pp. 57–59, Oct. 1989.
20. M. A. Karachunskiĭ, V. I. Gergert, and O. B. Iakovleva, "[Specific features of cellular immunity of pulmonary tuberculosis in patients with diabetes mellitus]," Probl. Tuberk., no. 6, pp. 59–60, 1997.
21. G. V. Budazhabon, B. I. Kuznik, V. G. Morozov, N. N. Orlova, and V. K. Khavinson, "[Immunogenesis and hemostasis in patients with exacerbated chronic glomerulonephritis treated with thymalin]," Ter. Arkh., vol. 56, no. 10, pp. 62–66, 1984.
22. I. F. Labunets', "[Age-related changes in circadian and circannual fluctuations of the immune response and the number of cells in lymphoid organs of animals: a possible connection to thymic factors]," Fiziolohichnyi Zhurnal Kiev Ukr. 1994, vol. 47, no. 5, pp. 54–62, 2001.
23. V. E. Ryzhenkov, R. P. Ogurtsov, V. V. Trubacheva, V. G. Popov, and V. P. Puzyreva, "[Effect of thymalin on the development of experimental hyperlipidemia and atherosclerosis]," Vopr. Med. Khim., vol. 34, no. 1, pp. 51–56, Feb. 1988.
24. 2Z. S. Zhumadilov and R. P. Terekhova, "[Use of thymalin for preventing postoperative suppurative and inflammatory complications]," Klin. Khirurgiia, no. 1, pp. 36–38, Jan. 1985.
25. B. I. Kuznik, V. K. Khavinson, V. G. Morozova, G. B. Budazhabon, and N. G. Budazhabon, "[Use of thymalin in treating periodontitis patients]," Stomatologiia (Sofiia), vol. 64, no. 1, pp. 20–22, Feb. 1985.
26. S. Wade et al., "Thymulin (Zn-facteur thymique serique) activity in anorexia nervosa patients," Am. J. Clin. Nutr., vol. 42, no. 2, pp. 275–280, Aug. 1985.